|
29 Aug 2023 |
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
|
|
29 Aug 2023 |
Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea® (aflibercept), by the U.S. Food and Drug Administration (FDA)
|
|
25 Aug 2023 |
Janssen Submits Supplemental Biologics License Application to the U.S. Food and Drug Administration Seeking Approval of RYBREVANT® (amivantamab-vmjw) in Combination with Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metast
|
|
25 Aug 2023 |
CD40 receptor and its ligand CD40L: versatile targets for improved product candidates
|
|
25 Aug 2023 |
Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA
|
|
25 Aug 2023 |
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
|
25 Aug 2023 |
Polpharma Biologics Announces FDA Approval of Tyruko® - First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple Sclerosis
|
|
24 Aug 2023 |
Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting
|
|
23 Aug 2023 |
TechBio Innovator Etcembly Reveals World’s First Generative AI-designed Bispecific T Cell Engager With Picomolar Affinity
|
|
23 Aug 2023 |
Vincerx Pharma Announces FDA Clearance of IND for VIP943
|
|
23 Aug 2023 |
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
|
|
23 Aug 2023 |
Anti-CD20 Monoclonal Antibody Rituxan® Approved for Lupus Nephritis that has Not Responded Sufficiently to Existing Therapies
|
|
22 Aug 2023 |
European Commission Approves TALVEY®▼ (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
|
22 Aug 2023 |
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
|
|
22 Aug 2023 |
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
|
|
19 Aug 2023 |
BITT Announces FDA Acceptance of IND for TNFR2 Antibody
|
|
19 Aug 2023 |
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
|
|
19 Aug 2023 |
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
|
|
19 Aug 2023 |
Fibroblast Activation Protein (FA): an ideal tumor stroma target for payload delivery
|
|
18 Aug 2023 |
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
|
|
18 Aug 2023 |
Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
|
|
18 Aug 2023 |
Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
|
|
18 Aug 2023 |
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
|
|
18 Aug 2023 |
European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI (teclistamab)
|
|
18 Aug 2023 |
NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
|
